Misgav Newsletter Q2 2008
A "Capital" Idea
As this newsletter highlights, there are a lot of great things happening in our portfolio companies. One of our primary challenges remains leveraging these great advances and raising the capital necessary to do so.
This month I would like to call your attention to four great Misgav Venture Accelerator companies that are currently looking to raise capital:
- HTL High Tech Lipids: HTL recently signed an agreement with a large European pharmaceutical company (see below) under which the Europeans commit to bring HTL's first product to market. Additionally, the two companies have submitted a joint application to a European-Israeli funding body. So what's missing? HTL needs to immediately raise $1 million in order to fund its share of the development costs.
- ID-U Biometrics: ID-U was recently named the IVA-Globes Start-Up of the Year! The company has also received Chief Scientist approval for a third year in the incubator and we are committed to investing a portion of the supplementary funding required. We are seeking either the balance of the supplementary funding or, alternatively, a large investment that would greatly accelerate the company's pace of development.
- Lavi Cardiatec: Lavi recently successfully completed its first clinical trials and also had its first patent issued -- two very important milestones. The company is concluding a first modest investment and is looking to raise $1-$2 million in order to launch its first product.
- JetGuide: Like Lavi, JetGuide recently completed very successful clinical trials at Rambam Medical Center. Additionally, the company is in serious commercial discussions with three world leaders in the medical device field. An investment of $2 million will enable the company to bring its first products to market.
Please feel free to contact me should you like information about any of these opportunities. You can also find information about all four companies on our website. Have a great summer! Steve Rhodes, CEO Misgav Venture Accelerator NEWS
| ID-U Takes First Place in IVA Start-Up Competition |
Congratulations to ID-U Biometrics, winner of this year's prestigious IVA-Globes Start-Up Competition. ID-U was the only incubator company among the finalists. The company is developing the world's first "dynamic" biometric system -- one that identifies individuals based on their reactions to a randomly generated external stimulus. Read the news item about ID-U Biometrics. |
| EnzySurge Raises $4 Million |
Chronic wound treatment company EnzySurge has raised $4 million at a company value of $12.3 million from private investors, led by chairman Eli Gilboa of the Gilboa and Licht accounting firm. EnzySurge develops innovative solutions for chronic wound management. Read the news item about EnzySurge. |
| High Tech Lipids Receives $5 Million Product Commitment |
High Tech Lipids has signed a memorandum of understanding with a European pharmaceutical company to invest $5 million in the company's NanoLip™ product. NanoLip is an advanced lipid emulsion for total parenteral nutrition (TPN) with significantly improved nutritional characteristics compared with the lipids that are currently administered intravenously. Read the news item about High Tech Lipids. |
| Immunovative Receives Patent Approvals |
|
|
| Lavi Cardiatec Receives Patent Approval |
Lavi Cardiatec was issued a patent for its "system for determining endothelial dependent vasoactivity." Lavi is developing a non-invasive device for early detection of endothelial dysfunction, an early risk factor in cardiovascular disease. Avner Amir is Lavi's CEO. Learn more about Lavi Cardiatec.
|
| Flexicath Featured in Globes |
| Flexicath and its catheter system, FirmGrip, were featured in a Globes article, "Cleanliness is key for catheters." The FirmGrip has a disposable silicone sleeve and unique "springback" mechanism for sterile catheter insertion. With its PeelGuard introducer, FirmGrip forms a "3D maximum barrier" that reduces infection and can stay in place for up to 29 days. Read the Globes article about Flexicath.
|
| Five Misgav Portfolio Companies Featured on Israel21c |
Read the full articles:
- "Israeli company delivers healthy fat to intravenous patients" (High Tech Lipids)
- "You'll never be me, with Israel's ID-U cyber identification" (ID-U Biometrics)
- "Israeli device holds out hope for heart patients" (Lavi Cardiatec)
- "Four Israeli women on a NeuroQuest" (NeuroQuest)
- "From cancer vaccines to a cure for allergies" (VacciGuard)
|
| Juvenis Names Santiago Ini as CEO |
|
Juvenis, our newest portfolio company, has named Santiago Ini, Ph.D., as its CEO. Santiago holds a Ph.D. in chemistry and did post-doctoral work in chemistry at Stanford. Previously he was a project manager at Teva.
Juvenis is developing Tenergel™, an innovative gel-like material that can be used to fill, repair, or augment soft tissue. The biodegradable liquid polymer increases in viscosity when exposed to tissue and fluids.
We wish Santiago good luck and success in his new position.
|
| BioSight Exhibits at Israeli Presidential Conference |
BioSight was featured in the exhibition "Tomorrow's Spaces" that was part of the Israeli Presidential Conference 2008 "Facing Tomorrow." The President's Conference was held in May. BioSight develops customized peptides and compounds with "pro-drug guided vectors" that can target and relase drugs directly into the site of a disease. Mark Gengrinovitch is BioSight's CEO. Learn more about BioSight.
|
| Nephera Unveils New Website |
Nephera has unveiled its new website at www.nephera.com. Nephera is developing an innovative medical device for patients suffering from chronic kidney disease. By forming negative pressure around the kidney, the Nephera device improves the functionality of the kidneys. Gill Bar-Yoseph is Nephera's CEO.
|
| BioPack's Professor Mansour Interviewed on Israeli Television |
Professor Fadel Mansour, founder and chief scientific office of BioPack was interviewed on the Hama'abadah ("The Laboratory") television program. The program features innovative technologies from the world of science and medicine. BioPack develops insect-repellent packaging and materials for the food industry and for agricultural and pest control uses. Learn more about BioPack.
©2008 The Misgav Venture Accelerator. All rights reserved |
|
